January 2015

Series A funding invested by Legend Capital & Legend Star (¥25 M)

September 2015

Moved in a new research and development Lab with 800m2 SPF animal facility and a 400m2 cell culture room. Located in PKU Healthcare Industrial Park.

February 2017

Series B funding lead by Panlin Capital (¥50 M)

April 2017

Sponsored Clinical Trial (investigator-initiated trial, IIT) “Rapid screening for individualized chemotherapy optimization of colorectal cancer with a novel conditional reprogramming technology-based functional diagnostic assay.”

August 2017

Launched new i-CR® technology platform Lauched RUO products for primary tumor cell: storage, isolation, in vitro culture and drug testing.

January 2018

Cothera Bioscience, Inc.Angel Investment ($5.5M).

May 2019

Restructured Cothera-Percans company builded an international team and an advanced basic research platform.

November 2019

License in PC-002

December 2020

Cothera Bioscience completed the series-B financing, and obtained USD 30 million of investment

June 2021

Cothera Receives Authorization from the FDA to Conduct a Phase 2 Clinical Trial to Test Its Targeted MYC Mutation Inhibitor PC-002 for the Treatment of High-Grade B-cell Lymphoma

September 2021

License in CDK inhibitor Zotiraciclib

September 2021

Cothera Receives Authorization from the FDA to Conduct a Phase 2 Clinical Trial to Test PC-002 for the Treatment of Neuroendocrine Prostate Cancer (NEPC)

March 2022

The NMPA has approved a Phase II clinical trial of PC-002 for high-grade B-cell lymphoma